OncoTherapy Science (TSE:4564) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円21.00
GF Value 円17.89
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoTherapy Science  (TSE:4564) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


OncoTherapy Science Cyclically Adjusted PB Ratio Related Terms


OncoTherapy Science Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Cyclically Adjusted PB Ratio Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 0.83 0.47 0.82 0.84

OncoTherapy Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.78 0.64 0.73 0.67

TSE:4564 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, OncoTherapy Science's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Cyclically Adjusted PB Ratio falls into.


TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

OncoTherapy Science's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, OncoTherapy Science's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.752/113.6000*113.6000
=5.752

Current CPI (Jun. 2026) = 113.6000.

OncoTherapy Science Quarterly Data

Book Value per Share CPI Adj_Book
201609 78.991 98.000 91.565
201612 74.185 98.400 85.644
201703 68.724 98.100 79.583
201706 64.709 98.500 74.629
201709 60.055 98.800 69.051
201712 56.706 99.400 64.807
201803 51.552 99.200 59.035
201806 46.668 99.200 53.442
201809 39.740 99.900 45.190
201812 36.894 99.700 42.038
201903 32.135 99.700 36.615
201906 30.261 99.800 34.445
201909 28.054 100.100 31.838
201912 26.774 100.500 30.264
202003 26.816 100.300 30.372
202006 24.496 99.900 27.855
202009 22.014 99.900 25.033
202012 19.598 99.300 22.420
202103 17.449 99.900 19.842
202106 17.506 99.500 19.987
202109 16.309 100.100 18.509
202112 12.465 100.100 14.146
202203 10.279 101.100 11.550
202206 8.665 101.800 9.669
202209 6.968 103.100 7.678
202212 5.461 104.100 5.959
202303 4.439 104.400 4.830
202306 4.499 105.200 4.858
202309 4.296 106.200 4.595
202312 3.015 106.800 3.207
202403 1.625 107.200 1.722
202406 2.795 108.200 2.934
202409 3.683 108.900 3.842
202412 3.051 110.700 3.131
202503 2.684 111.100 2.744
202506 3.548 111.700 3.608
202509 4.861 112.000 4.930
202512 5.679 113.000 5.709
202603 5.583 112.700 5.628
202606 5.752 113.600 5.752

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円21.00 is trading 17.4% above its estimated GF Value™ of 円17.89. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: 円17.89 vs. price of 円21.00 (17.4% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円21.00
Price
円17.89
GF Value